Sexual dysfunction in male schizophrenia: influence of antipsychotic drugs, prolactin and polymorphisms of the dopamine D2 receptor genes by Zhang, X et al.
ReseaRch aRticle
ISSN 1462-2416Pharmacogenomics (2011) 12(8) 1127–113610.2217/PGS.11.46 © 2011 Future Medicine Ltd 1127
Sexual dysfunction in male schizophrenia:  
influence of antipsychotic drugs, prolactin and 
polymorphisms of the dopamine D2 receptor genes
Antipsychotic-induced sexual dysfunction (AP-
SD) is a common and serious clinical side effect 
that is under investigated and under reported. 
Epidemiological research has reported sub-
stantial variations in the general prevalence of 
AP-SD, which ranges from approximately 30 
to 80% [1]. SD has important implications for 
satis faction with sexual life and overall quality of 
life [2,3]; it has been demonstrated as one of the 
major reasons for treatment noncompliance and 
inevitably affects clinical outcome and treatment 
success [4–6]. The differences in individual liabil-
ity indicate the possible importance of genetic 
factors in determining the emergence of AP-SD.
The mechanisms of AP-SD remain largely 
unclear, and current theories derive mainly 
from studies of general sex physiology and 
psycho–pharmacology. The responses of vari-
ous sexual components are under the control of 
numerous central and peripheral neural systems 
[7,8]. It has been postulated that a direct dopamine 
D2 receptor antagonist effect of antipsychotics 
may be the primary central mechanism, along 
with some indirect neuroendocrine factors, such 
as elevated prolactin levels [9]. Typical antipsy-
chotics (e.g., haloperidol and thioridazine) are 
generally considered to cause relatively more 
SD than atypical agents (e.g., clozapine, olan-
zapine and quetiapine) and this has been ascribed 
to differences in affinity at D2 receptors [1,10]. 
Increased prolactin following antipsychotics has 
been suggested to suppress every aspect of sexual 
function (i.e., desire, erection and orgasm) [11], 
although this proposal remains controversial [12]. 
Two well-studied polymorphisms of the dopa-
mine D2 receptor gene (DRD2), -141C Ins/Del 
and Taq1A, have been reportedly associated 
with dopamine D2 receptor density in in vitro 
studies [13] and in human striatum [14,15], respec-
tively. Decreased dopamine D2 receptor density 
could theoretically result in greater vulnerability 
to dopamine blockade and hence an increased 
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occurrence of significant side effects, possibly 
including SD. This is supported by the finding 
that patients with a DRD2 Taq1 A1 allele, asso-
ciated with decreased brain receptor densities, 
had relatively higher prolactin levels following 
antipsychotic drug treatment [16].
We recently demonstrated that the gene 
expression and activity of nitric oxide synthase 
(NOS) isoforms are differentially affected by 
chronic antipsychotic treatment in rat penile 
tissues, indicating that peripheral mechanisms 
involving nitric oxide activity might also be 
involved in the pathogenesis of sexual side 
effects [17]. Interestingly, the eNOS G894T 
polymorphism was the first SNP shown to be 
associated with an increased risk of erectile dys-
function (ED) in two different racial popula-
tions [18,19]. The eNOS T-786C polymorphism, a 
functional promoter SNP [20], has been linked to 
an increased risk of developing coronary artery 
disease [21,22], which might also be relevant to 
the hemodynamics of penile erection.
The paucity of reports exploring the 
pharmaco genetics of AP-SD has prompted us 
to investigate the possible association with male 
AP-SD of these four potentially functional 
SNPs in two strong candidate genes, in order 
to better understand the mechanisms contrib-
uting to individual variability in SD in patients 
with schizophrenia.
Materials & methods
 n Subjects 
The subjects were Chinese Han outpatients 
recruited from the psychiatric outpatient unit 
and four community psychiatric centers. All 
subjects provided written informed consent 
for participation in the study, which had been 
approved by the Hospital Ethical Committee, 
in accordance with the Declaration of Helsinki. 
Eligibility criteria for inclusion into the study 
were as follows: 
  A married remitted male schizophrenia out-
patient living with a stable sexual partner for 
the previous 6 months; 
  Aged between 25 and 45 years; 
  Medication with a single antipsychotic drug 
for at least 6 months. 
Remitted schizophrenia was defined by 
two components: a Diagnostic and Statistical 
Manual of Mental Disorders-IV diagnosis of 
schizo phrenia as established by the clinic phy-
sician, coupled with a current state of remission 
defined by the symptomatic criteria proposed 
by the Remission in Schizophrenia Working 
Group [23], excepting the requirement for 
continuous state of remission over 6 months. 
Patients were excluded if they had one or more 
of the following: 
  Any reported history of SD before anti psychotic 
treatment; 
  A general medical condition or history of a 
surgical procedure known to cause SD, for 
example prostatectomy, diabetes, hypertension 
or neurological disease; 
  Any other side effect of antipsychotics, for 
example, tardive dyskinesia, which might 
indirectly influence sexual function or its 
reporting; 
  Receiving other psychotropic drugs known to 
cause SD, for example antidepressants, 
although patients taking other adjunctive 
medications, such as anticholinergics and 
benzodiazepines, were not excluded; 
  Any history of substance or alcohol abuse.
 n Clinical features & sexual function
Subjects were told they would participate in a 
brief survey to evaluate their experiences with 
their current psychiatric medications. A medical 
history was obtained, including:
  Demographic information; 
  History of past illness and treatment; 
  Currently prescribed psychotropic medications 
and duration of treatment. 
The antipsychotic dose was calculated as chlor-
promazine equivalent in mg/day. All patients 
were then rated using the Positive and Negative 
Syndrome Scale (PANSS) on the day of recruit-
ment by the senior psychiatrists. The patient’s 
psychiatric symptom severity over the previous 
6 months was obtained from their treating clini-
cal psychiatrist in the psychiatric outpatient unit 
and community psychiatric centers.
After obtaining demographic and medica-
tion/treatment information, sexual function was 
evaluated with a one-time rating of two five-item 
self-administered questionnaires: the Arizona 
Sexual Experience Scale (ASEX) [24] and the 
abridged five-item version of the International 
Index of Erectile Function (IIEF-5) [25]. The 
ASEX, assessing the severity of overall SD, 
has established psychometric properties (inter-
nal reliability and construct and convergent 
validity) in outpatients with schizophrenia or 
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schizoaffective disorder [26]. The criterion for 
SD, according to the ASEX, is a total score of 
19 or above, any one item with an individual 
score of 5, or any three items with individual 
score of 4 [24]. The IIEF-5 focused on ED and 
intercourse satisfaction, while each item is scored 
on a five-point ordinal scale, where lower val-
ues represent poorer sexual function. A score of 
above 21 is considered normal erectile function 
and, at or below this threshold, is considered as 
ED [25]. Validated versions for China were used 
in the present study. The participants undertook 
this in an individual room with a total guaran-
tee of confidentiality. If needed, the psychiatrist 
provided any necessary explanation to ensure the 
questionnaires were understood. 
 n Prolactin measurement
Blood was collected after an overnight fast in 
a 5-ml EDTA vacuum tube from each patient 
and then centrifuged at 3000 rpm for 5 min to 
separate the plasma from cells; these were frozen 
and stored at -70°C until prolactin measurement 
and genotyping, respectively. Plasma prolactin 
was assayed in duplicate by double antibody 
radio immunoassay. The reagents were provided 
in kits from Jiuding Biological Corporation, 
China. The inter- and intra-assay coefficients of 
variation were 5.6 and 5.9%.
 n Genotyping
After extraction of genomic DNA from blood 
cells, genotyping was performed by PCR–
restriction fragment length polymorphism tech-
nique, using methods as previously described: 
DRD2 Taq1A [27,28], DRD2 -141C Ins/Del 
[13,29], eNOS G894T [30] and eNOS T-786C [31]. 
The resulting segments were digested with the 
restriction endonuclease TaqI for Taq1A, BstNI 
for -141C Ins/Del, BanII for G894T and MspI 
for T-786C (New England BioLabs, UK) and 
products separated by electrophoresis on 3% 
agarose gel stained with ethidium bromide.
 n Statistical ana lysis
All statistical analyses were performed using 
SPSS 11.5 for Windows employing two-tailed 
tests. Values of demographic characteristics and 
questionnaire scores are given as mean ± stan-
dard deviation. Differences in clinical variables 
or in PANSS scores between patient subgroups 
were evaluated by t-test or ana lysis of vari-
ance. Differences in sexual function between 
allele and genotype groups were evaluated with 
Mann–Whitney U and Kruskal–Wallis H 
tests as the ASEX and IIEF-5 scores were not 
normally distributed, while prolactin measures 
were log-transformed prior to ana lysis of vari-
ance. Chi-square tests were used to compare 
allele and genotype frequencies, and drug treat-
ments, between the different sexual function 
subgroups. Power ana lysis demonstrated that 
the sample size had 80% power to identify sig-
nificant frequency differences in SD with odds 
ratios of approximately 1.75.
Results
 n Clinical demographic characteristics 
& blood prolactin in male 
schizophrenic patients
A total of 176 psychiatric outpatients meeting 
the inclusion criteria were initially identified, 
of whom, 100 subjects finally provided written 
informed consent and participated in the study. 
Those patients received antipsychotic mono-
therapy with clozapine (n = 37), risperidone 
(n = 30), chlorpromazine (n = 21), haloperidol 
(n = 9) and olanzapine (n = 3). Using the cut-off 
level of the ASEX questionnaire, the patients were 
divided into two groups, the SD group (n = 47) 
with a mean ASEX score of 23.57 (± 3.02) and 
the normal sexual functioning group (n = 53) 
with a mean ASEX score of 13.19 (± 2.36). 
The clinical features of the SD and non-SD 
groups demonstrated no significant differences 
in age (40.6 ± 5.4 years and 41.0 ± 4.6 years, 
respectively), length of current drug treatment 
(8.32 ± 3.9 years and 6.91 ± 3.2 years, respec-
tively), age of onset, chlorpromazine equivalent 
dosage or PANSS score. According to the IIEF-5 
score, 45 patients were in the ED group. Again, 
there were no significant differences found in 
any socio–demographic and clinical variables 
between the erectile function groups divided 
according to IIEF-5 criteria. 
 n Genetic association with 
sexual dysfunction
The genetic association of alleles and geno-
types of the DRD2 and eNOS polymorphisms 
with sexual and erectile function are shown in 
Tables 1 & 2. Where a single homozygous subject 
was found in the sample studied (for DRD2 
-141C Del/Del, and for eNOS 894TT), these 
samples were included in the heterozygote 
groups for further ana lysis. For eNOS -786 there 
were no CC homozygotes within the sample. 
The distribution of genotypes in each polymor-
phism did not differ significantly from Hardy–
Weinberg equilibrium. There were no significant 
associations found for either of the eNOS poly-
morphisms or the DRD2 Taq1A polymorphism 
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with either SD or ED. Analysis of the Taq1A 
polymorphism using dominant or recessive 
models also showed no significant association. 
These polymorphisms also showed no significant 
associations with clinical features of the patients 
studied, or with prolactin measurements (data 
not shown). 
Significant association with SD determined by 
ASEX criteria was found for the -141C Ins/Del 
polymorphism in the DRD2 gene (Table 1). The 
DRD2 -141C Del allele was found to be signifi-
cantly less frequent in SD patients than non-SD 
group (odds ratio: 0.258; 95% CI: 0.071–0.945; 
p = 0.003). The genotype distribution reflected 
this effect, with a significantly lower frequency 
of Del allele carriers in the SD group (odds ratio: 
0.260; 95% CI: 0.068–0.999; p = 0.046). The 
same trend towards genotype and allelic asso-
ciations was apparent for ED determined by 
IIEF-5 criteria, although results did not quite 
reach statistical significance (Table 2). The dif-
ference between the two measures was due 
to two  subjects meeting SD criteria but not 
reporting ED. 
Comparison of ASEX outcomes showed worse 
sexual function in the Ins/Ins genotype patient 
group than the -141C Del carriers (Table 3). The 
analyses also revealed a significant genotype 
association with three of the five ASEX indi-
vidual subitems. Although the IIEF-5 total score 
did not differ significantly between -141C Del 
carriers and Ins/Ins homozygotes, a significant 
difference was found in two IIEF-5 individual 
subitems (3 and 4; p = 0.016 and 0.011, respec-
tively). The -141C Del carriers had a longer 
duration of illness than the -141C Ins/Ins geno-
type group, but no other significant differences 
in socio–demographic and PANSS scores were 
found between the two genotype groups.
 n Prolactin & sexual dysfunction
The difference in blood prolactin between the SD 
(22.4 ± 18.9 ng/ml) and non-SD (17.9 ± 16.5 ng/ml) 
groups did not reach significance (p = 0.058). 
A significant difference in blood prolactin was 
found between the ED (23.4 ± 19.2 ng/ml) and 
non-ED (17.0 ± 16.0 ng/ml) groups (p = 0.017). 
Correlation ana lysis showed significant or 
Table 1. Distributions of genotypes and alleles between sexual dysfunction and normal sexual function groups 
of schizophrenic patients determined by the Arizona Sexual Experience Scale.
Genotypes SD Normal c2 Alleles SD Normal c2
DRD2 -141C Ins/Del Del/Ins + Del/Del 3 11 c2 = 4.273 Del 3 12 c2 = 4.746
Ins/Ins 44 42 df = 1; p = 0.046 Ins 91 94 df = 1; p = 0.003
DRD2 Taq1A A1A1 9 8 c2 = 0.463 A1 40 40 c2 = 0.482
A1A2 22 24 df = 2; p = 0.793 A2 54 66 df = 1; p = 0.488
A2A2 16 21
eNOS T-786C TC 12 8 c2 = 1.696 C 12 8 c2 = 1.508
TT 35 45 df = 1; p = 0.193 T 82 98 df = 1; p = 0.219
eNOS G894T GG 39 45 c2 = 0.069 G 86 97 c2 < 0.001
GT + TT 8 8 df = 1; p = 0.793 T 8 9 df = 1; p = 0.996
The different sexual function groups were divided according to the cut-off level of Arizona Sexual Experience Scale. 
Comparisons between groups were made using c2 tests.
Del: Deletion; df: Degrees of freedom; DRD2: D2 dopamine receptor; eNOS: Endothelial nitric oxide synthase; Ins: Insertion; SD: Sexual dysfunction.
Table 2. Distributions of genotypes and alleles between erectile dysfunction and normal erectile function 
groups of schizophrenic patients determined by the International Index of Erectile Function-5.
Genotypes ED Normal c2 Alleles ED Normal c2
DRD2 -141C Ins/Del Del/Ins + Del/Del 3 11 c2 = 3.654 Del 3 12 c2 = 4.095
Ins/Ins 42 44 df = 1; p = 0.082 Ins 87 98 df = 1; p = 0.058
DRD2 Taq1A A1A1 9 8 c2 = 0.738 A1 39 41 c2 = 0.758
A1A2 21 25 df = 2; p = 0.691 A2 51 69 df = 1; p = 0.384
A2A2 15 22
eNOS T-786C TC 11 9 c2 = 1.01 C 11 9 c2 = 0.898
TT 34 46 df = 1; p = 0.315 T 79 101 df = 1; p = 0.343
eNOS G894T GG 36 48 c2 = 0.974 G 81 102 c2 = 0.491
GT + TT 9 7 df = 1; p = 0.324 T 9 8 df = 1; p = 0.706
The different erectile function groups were divided according to the cut-off level of the International Index of Erectile Function-5. 
Comparisons between groups were made using c2 tests.
Del: Deletion; df: Degrees of freedom; DRD2: D2 dopamine receptor; ED: Erectile dysfunction; eNOS: Endothelial nitric oxide synthase; Ins: Insertion.
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near-significant effects between prolactin concen-
trations and IIEF-5 and ASEX scores (p = -0.191, 
p = 0.028 and p = 0.157, p = 0.059, respectively; 
Spearman’s test, one-tailed). 
Prolactin concentrations were found to be 
highly significantly associated with the DRD2 
-141C polymorphism, with the Ins/Ins geno-
type associated with significantly higher values 
than Del allele carriers (Table 3). No significant 
association of prolactin concentrations with any 
other polymorphism studied was apparent (data 
not shown).
 n Effect of antipsychotic drugs on 
severity of sexual dysfunction & 
blood prolactin
To assess whether the drug treatments differen-
tially influenced SD, the sample was divided into 
three subgroups: those receiving cloza pine, risper-
idone or typical antipsychotic drugs (chlorprom-
azine and haloperidol). Comparison of ASEX 
and IIEF-5 scores between anti psychotic drug 
groups revealed a significant treatment effect on 
severity of SD, as measured by ASEX total scores 
(p = 0.016) but not by IIEF-5 (p = 0.207). Posthoc 
tests showed that the ASEX total scores were 
higher in the typical antipsychotic drug group 
(20.73 ± 5.56) than in the clozapine (17.24 ± 6.08; 
p = 0.018) or risperidone (17.06 ± 5.17; p = 0.007) 
groups, indicating worse sexual function in the 
typical antipsychotic drug group than the other 
two subgroups. These findings were reflected in 
the greater proportion of subjects receiving typical 
antipsychotics reaching threshold criteria for SD 
and ED (66.7 and 60.7%, respectively) than in 
the clozapine (40.5 and 37.8%) and risperidone 
(40.0 and 43.3%) groups. 
Prolactin showed significant differences between 
the drug groups, in which blood concentrations 
in the risperidone group (31.9 ± 22.3 ng/ml) 
were substantially and significantly higher than 
either the typical (17.8 ± 13.0 ng/ml; p = 0.042) 
or the clozapine (12.1 ± 10.1 ng/ml; p < 0.001) 
groups. The effect of prolactin on sexual func-
tion was explored further within the three drug 
groups. An effect was only apparent in the risperi-
done group where correlations between prolac-
tin concen trations and IIEF-5 and ASEX scores 
showed significant or near-significant correlations 
(p = -0.384, p = 0.018 and p = 0.304, p = 0.051; 
Spearman’s test, one-tailed).
Discussion
In the present study, the severity and preva-
lence of SD in response to antipsychotic agents 
was evaluated in remitted male schizophrenia 
patients based on ASEX and IIEF-5 rating scales. 
The main findings of our study were in keeping 
with most previous reports that SD is common 
in male schizophrenia patients on antipsychotic 
medication [32], with 47 and 45% reaching 
threshold criteria for SD and ED, respectively, 
higher than the rate of such dysfunction in the 
general population (10–31%) [33–35]. 
Results are, on the whole, generally consis-
tent between the IIEF-5 (ED) and ASEX (SD) 
measures. As mentioned, the difference between 
those in the ED and SD groups reflects two 
subjects reaching criteria for SD but not ED. 
Greater differences are seen in statistical tests 
of the scores from each questionnaire, reflect-
ing substantial differences between the two 
measures. Thus SD, determined by the ASEX 
questionnaire, provides a far broader assessment 
of sexual function than IIEF-5, which focuses 
solely on erectile function.
To our knowledge, this is the first study to 
investigate genetic mechanisms of AP-SD in 
remitted male patients with schizophrenia. Our 
findings indicate a significant involvement of 
the DRD2 -141C Ins/Del polymorphism in SD, 
following antipsychotic drug treatment. In this 
Table 3. Comparison of sexual function and clinical features in the 
DRD2 -141C Ins/Del genotype group.
Outcome measure Del/Ins +  
Del/Del
(n = 14)
Ins/Ins
(n = 86)
p-value
Total ASEX score
– Sex drive
– Arousal
– Penile erection
– Orgasm (ability)
– Orgasm (satisfaction)
14.9 ± 4.0
3.6 ± 0.9
3.1 ± 1.1
2.5 ± 0.8
2.6 ± 0.7
3.1 ± 1.1
18.6 ± 6.0
4.0 ± 1.1
3.8 ± 1.2
3.4 ± 1.3
3.7 ± 1.4
2.7 ± 1.4
0.021
0.129
0.032
0.007
0.013
0.117
Total IIEF-5 score
– Erection confidence
– Erection firmness
– Maintenance frequency
– Maintenance ability
– Intercourse satisfaction
22.0 ± 1.9
3.9 ± 0.5
4.4 ± 0.6
4.9 ± 0.4
4.7 ± 0.5
4.2 ± 0.7
18.5 ± 6.0
3.4 ± 1.1
3.9 ± 1.3
3.9 ± 1.4
3.7 ± 1.4
3.6 ± 1.4
0.171
0.177
0.535
0.016
0.011
0.166
Age (years) 41.1 ± 4.6 40.7 ± 5.0 0.976
Age of onset (years) 24.2 ± 4.6 26.8 ± 4.8 0.069
Duration of schizophrenia 16.9 ± 4.9 14.0 ± 5.2 0.027
Dose 300.0 ± 123.6 336.0 ± 125.3 0.434
Total Positive and Negative 
Syndrome Scale
46.8 ± 6.1 47.5 ± 5.2 0.62
Positive subscore 12.2 ± 2.6 12.6 ± 2.2 0.514
Negative subscore 11.5 ± 2.2 11.9 ± 2.3 0.53
General subscore 23.1 ± 2.7 23.0 ± 2.6 0.936
Prolactin (ng/ml) 12.2 ± 13.6 21.3 ± 18.1 0.004
Data are expressed as mean ± standard deviation. 
ASEX: Arizona Sexual Experience Scale; Del: Deletion; DRD2: D2 dopamine receptor;  
IIEF-5: International Index of Erectile Function-5; Ins: Insertion.
For reprint orders, please contact: reprints@futuremedicine.com
ReseaRch aRticle Zhang, Zhang, Zhu, Yuan, Jenkins & Reynolds
future science group1132 Pharmacogenomics (2011) 12(8)
Chinese Han population, the prevalence of SD 
in Del allele carriers (Del/Ins + Del/Del) was 
significantly lower than in Ins/Ins homozygotes 
with relatively better rating scale scores. Blood 
prolactin was also lower in Del allele carriers. 
Our findings suggested a protective effect of 
the DRD2 -141C Del allele on sexual function 
 following  antipsychotic drug administration. 
The -141C Ins/Del polymorphism has been 
reported to influence dopamine D2 receptor 
availability, with the Del allele being associated 
with a reduction of D2 receptor expression [13]. 
However, a PET study performed in healthy 
individuals revealed a higher striatal density of 
D2 receptors in -141C Del allele carriers [36]. 
This in vivo study provided the neuroimag-
ing evidence for the -141C Del allele being a 
possible indicator of resistant response to anti-
psychotic medication. There have been several 
recent studies supporting this hypothesis. A 
study on Chinese Han population reported that 
schizophrenia patients carrying the Del allele 
showed less improvement following chlorprom-
azine treatment than those who did not; the 
frequency of the Del allele was also higher in 
nonresponders than in responders [37]. Another 
study on patients with first-episode schizophre-
nia, further indicated that relative to Ins/Ins 
homozygotes, -141C Del carriers took a sig-
nificantly longer time to respond to olanza pine 
or risperidone treatment [38]. Taken together, 
these findings indicate that antipsychotics may 
be associated with a relative lower pharmaco-
logical efficacy in -141C Del alleles carriers and 
further suggest the possibility of the -141C Del 
allele as a protective factor for AP-SD.
It has been reported that the TaqA1 allele 
of the DRD2 gene is associated with signifi-
cantly decreased D2 receptor density, which 
may influence D2 receptor antagonism [14]. 
Patients with the DRD2 A1 allele receiving 
antipsychotic medications were reported to have 
higher prolactin levels than patients without 
this allele [16], which indicated a possible link 
between the Taq1A polymorphism and AP-SD. 
However, we found no significant association 
of the Taq1A poly morphism of the DRD2 
gene with susceptibility to sexual side effects 
in our study. A recent report indicated a pos-
sible racial effect for the Taq1A polymorphism 
in its association with the overall level of side 
effects (i.e., including SD) due to antipsychotic 
medication [39]. This association was found in 
Caucasian subgroups, but disappeared if three 
subjects with Asian ethnicity were included in 
the statistical ana lysis [39].
The hormone prolactin has been also regarded 
as a causative factor underlying AP-SD [9]. 
The present study demonstrated elevations of 
blood prolactin in patients with SD, especially 
ED. Previous studies have shown that prolac-
tin can suppress sexual behavior in both male 
patients [40,41] and rodents [42], although it is 
still not fully understood how this hormone 
affects the sexual capacity of male subjects. 
Several studies have found a significant corre-
lation between prolactin and male sexual side 
effects [43–45], while others have failed to confirm 
these findings [12,46,47]. Interestingly, it has been 
suggested that only severe hyperprolactinemia 
is associated with human SD [48]. Given that 
prolactin elevation following antipsychotic 
drug treatment is primarily due to dopamine 
D2 receptor antagonism, it seems possible that 
the effect of the DRD2 genotype on SD may be 
mediated through its effects on prolactin con-
centration. However, we found that prolactin 
concentrations correlated with ED only within 
the risperidone group, in which blood prolactin 
was substantially higher than in the clozapine 
or typical antipsychotic groups. Moreover, the 
risperidone group, despite having a higher mean 
level of prolactin, had less SD compared with 
patients receiving typical antipsychotic drugs. 
This is in keeping with a previous report indi-
cating that the increased prolactin associated 
with risperidone treatment does not seem to be 
decisive for SD [47]. These observations strongly 
suggest that a DRD2-mediated prolactin eleva-
tion is not the only factor contributing to AP-SD 
in male patients with schizophrenia.
It is worth noting that both severity and 
prevalence of SD are generally lower with atypi-
cal antipsychotics than typical anti psychotics 
[49,50]. While some have reported that the fre-
quency of SD induced by risperidone was higher 
than the other atypical antipsychotics, such as 
clozapine [51] and olanzapine [52], other stud-
ies, along with the present finding, suggest that 
risperidone is associated with a degree of SD 
similar to clozapine [53], olanzapine [54] and 
quetiapine [49]. The inconsistencies between 
these various reports might be attributed to a 
variety of influences and confounders, includ-
ing, clinical factors of schizophrenia (e.g., psy-
chiatric symptoms, comorbid conditions and 
comedication regimes) [55] and methodological 
factors including different assessment tools for 
sexual behavior and differences in study sam-
ples (e.g., subjects’ sex and trial design) [10]. 
Attempting to address some of these limitations, 
the present study evaluated sexual function in 
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remitted schizophrenia patients within a stable 
sexual relationship, using questionnaires that 
had been tested for their reliability and validity 
in schizophrenia. 
Apart from DRD2 and prolactin, other mecha-
nisms, including effects at the serotonin (5-HT) 
2A receptor, might also contribute to the observed 
differences in SD between risperidone and typi-
cal antipsychotics, counteracting the effects of 
elevated prolactin. Both risperidone and clozapine 
have higher affinities for the 5-HT2A than the 
D2 receptor [56]. 5-HT2A antagonism has been 
demonstrated to have a strong stimulating effect 
on male sexual behavior in several animal studies 
[57,58]. However, further pharmacological mecha-
nisms, or indirect effects via the elevation of other 
risk factors for SD, may well contribute to AP-SD.
The relationship between two SNPs 
(G987T and T-786C) of the eNOS gene and 
AP-SD was also determined. The G894T poly-
morphism had been reported to be a genetic 
susceptibility factor for ED in Mexican and 
Taiwanese populations [18,19]. However, a study 
in the German population did not find the 
association of this SNP with ED, but reported 
association of the G894 allele with response 
to sildenafil, a drug acting on the NO-cGMP 
pathway in erectile tissues [59]. In the pres-
ent study, we did not detect any association 
between either SNP of the eNOS gene and 
AP-SD. However, given the evidence impli-
cating eNOS in anti psychotic-induced sexual 
function, it would be premature to rule it out 
as a candidate gene for susceptibility to sex-
ual side effects. An important role of eNOS in 
AP-SD has been established by the results of 
our animal study [17]. Moreover, sildenafil has 
also been found to be a safe and effective drug 
in the treatment of antipsychotic-induced ED 
[60,61]. Therefore, further functional polymor-
phisms of eNOS or other genes involved in the 
NO-cGMP pathway might still be risk factors 
for antipsychotic-induced SD.
This study had several limitations; as a cross-
sectional study, it was not possible to determine 
the direct effect of antipsychotic treatment on 
the extent and severity of SD because of the 
absence of baseline ASEX and IIEF-5 ratings 
prior to treatment. Furthermore, while the 
study was powered to identify robust effects of 
genetic subgroups on SD, further investigation 
of subgroups, or interaction between treatment 
and genetic effects for example, was not justi-
fied with the sample size. The effects of four 
polymorphisms in two different genes have 
been tested for their association with measures 
of SD. While a separate valid hypothesis justi-
fies the investigation of each gene, there is an 
element of multiple testing in this study that 
has not been corrected for by adjustment of 
p-values. However, even with the most conser-
vative correction, it is clear that the association 
of the D2 -141C allele with SD would remain 
statistically signif icant. Nevertheless, the 
results of any small study such as this, needs 
to be considered as preliminary and awaiting 
replication in further cohorts before robust 
conclusions can be drawn. In addition, larger 
samples would be required to ascertain more 
precisely, the genetic effect on sexual function 
following specific medications, or to deter-
mine the interactions between D2 receptor 
genotype, prolactin and drug in contributing 
to AP-SD. Given the differences between drugs 
in D2 receptor affinity and effects on prolac-
tin, it may be that receptor genotype would 
differentially influence SD following different 
drug treatments.
Nevertheless, our findings indicate that the 
typical antipsychotics are more likely to be asso-
ciated with SD in men than the atypical drugs, 
including risperidone and clozapine, despite the 
higher blood prolactin concentrations associ-
ated with risperidone. In addition to pharma-
cological mechanisms of antipsychotic medica-
tion, genetic factors may also be important in 
determining AP-SD. The present genetic find-
ing may help to predict the possible influence 
of anti psychotic treatment on sexual function, 
which has implications in the improvement of 
treatment compliance and the quality of life of 
patients with schizophrenia.
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